Bafna Pharmaceuticals Financial Statements
Bafna Pharmaceuticals Balance Sheet
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
| Growth matrix (%) | ||||
| Revenue growth | (2) | (8.10) | (27) | (24) |
| Op profit growth | (109) | (62) | 505 | (1,225) |
| EBIT growth | (89) | 108 | (13) | 276 |
| Net profit growth | 31 | 12.80 | (14) | 38.70 |
| Profitability ratios (%) | ||||
| OPM | 2.88 | (31) | (74) | (8.90) |
| EBIT margin | (4.20) | (37) | (16) | (14) |
| Net profit margin | (58) | (44) | (35) | (30) |
| RoCE | (2.80) | (20) | (7.20) | (6.60) |
| RoNW | (18) | (17) | (10) | (9.70) |
| RoA | (9.90) | (5.90) | (3.90) | (3.60) |
| Per share ratios () | ||||
| EPS | -- | -- | -- | -- |
| Dividend per share | -- | -- | -- | -- |
| Cash EPS | (118) | (9.40) | (8.80) | (13) |
| Book value per share | 216 | 8.06 | 16 | 22.90 |
| Valuation ratios | ||||
| P/E | -- | -- | -- | -- |
| P/CEPS | (0.10) | (1.20) | (3.20) | (2.30) |
| P/B | 0.04 | 1.36 | 1.75 | 1.29 |
| EV/EBIDTA | (2.30) | (5.50) | (29) | (29) |
| Payout (%) | ||||
| Dividend payout | -- | -- | -- | -- |
| Tax payout | -- | 5.84 | 14.90 | (4.40) |
| Liquidity ratios | ||||
| Debtor days | 133 | 207 | 302 | 342 |
| Inventory days | 88.90 | 84 | 106 | 93 |
| Creditor days | (231) | (219) | (116) | (159) |
| Leverage ratios | ||||
| Interest coverage | 18.70 | 7.60 | 1.12 | 0.77 |
| Net debt / equity | (0.10) | 2.28 | 1.15 | 1.87 |
| Net debt / op. profit | (4.50) | (3.30) | (1.20) | (14) |
| Cost breakup () | ||||
| Material costs | (47) | (64) | (81) | (80) |
| Employee costs | (24) | (21) | (16) | (10) |
| Other costs | (26) | (46) | (77) | (19) |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
| Revenue | 42.50 | 43.40 | 47.20 | 65 |
| yoy growth (%) | (2) | (8.10) | (27) | (24) |
| Raw materials | (20) | (28) | (38) | (52) |
| As % of sales | 47.10 | 64.10 | 81.20 | 79.90 |
| Employee costs | (10) | (9) | (7.50) | (6.80) |
| As % of sales | 24.10 | 20.80 | 15.80 | 10.50 |
| Other costs | (11) | (20) | (37) | (12) |
| As % of sales | 25.90 | 45.90 | 77.50 | 18.50 |
| Operating profit | 1.22 | (13) | (35) | (5.80) |
| OPM | 2.88 | (31) | (74) | (8.90) |
| Depreciation | (3.30) | (3.50) | (4) | (4.20) |
| Interest expense | (0.10) | (2.10) | (6.90) | (11) |
| Other income | 0.26 | 0.65 | 31.30 | 1.14 |
| Profit before tax | (1.90) | (18) | (15) | (20) |
| Taxes | -- | (1.10) | (2.20) | 0.90 |
| Tax rate | -- | 5.84 | 14.90 | (4.40) |
| Minorities and other | (0.30) | (0.50) | 0.17 | -- |
| Adj. profit | (2.20) | (20) | (17) | (19) |
| Exceptional items | (23) | 1.01 | -- | -- |
| Net profit | (25) | (19) | (17) | (19) |
| yoy growth (%) | 31 | 12.80 | (14) | 38.70 |
| NPM | (58) | (44) | (35) | (30) |
- Switch to
-
Tabular DataGraph
| Y/e 31 Mar ( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
| Profit before tax | (1.90) | (18) | (15) | (20) |
| Depreciation | (3.30) | (3.50) | (4) | (4.20) |
| Tax paid | -- | (1.10) | (2.20) | 0.90 |
| Working capital | (55) | (93) | (94) | (34) |
| Other operating items | -- | -- | -- | -- |
| Operating cashflow | (60) | (115) | (115) | (58) |
| Capital expenditure | (14) | (13) | (11) | 2.29 |
| Free cash flow | (74) | (129) | (126) | (55) |
| Equity raised | 103 | 68.10 | 86.20 | 96.60 |
| Investments | -- | -- | -- | -- |
| Debt financing/disposal | (82) | (54) | (62) | 13.70 |
| Dividends paid | -- | -- | -- | -- |
| Other items | -- | -- | -- | -- |
| Net in cash | (54) | (114) | (101) | 55 |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar ( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
| Equity capital | 57.70 | 23.70 | 23.70 | 22.70 |
| Preference capital | -- | -- | -- | -- |
| Reserves | (6.60) | (4.60) | 14.30 | 20 |
| Net worth | 51.10 | 19.10 | 37.90 | 42.70 |
| Minority interest | ||||
| Debt | 3.02 | 46.20 | 46.50 | 82.40 |
| Deferred tax liabilities (net) | -- | 6.18 | 5.11 | 2.92 |
| Total liabilities | 54.20 | 71.30 | 88.90 | 127 |
| Fixed assets | 35.20 | 37.10 | 44.90 | 48.60 |
| Intangible assets | ||||
| Investments | -- | -- | -- | 16.90 |
| Deferred tax asset (net) | -- | -- | -- | -- |
| Net working capital | 10.50 | 31.50 | 41 | 59.30 |
| Inventories | 11.40 | 9.28 | 10.70 | 16.70 |
| Inventory Days | 98.10 | 78.10 | 82.60 | 94.10 |
| Sundry debtors | 6.03 | 24.80 | 24.30 | 53.80 |
| Debtor days | 51.80 | 209 | 188 | 302 |
| Other current assets | 10.20 | 45.60 | 55.60 | 39.60 |
| Sundry creditors | (13) | (40) | (29) | (24) |
| Creditor days | 108 | 333 | 221 | 134 |
| Other current liabilities | (4.60) | (8.70) | (21) | (27) |
| Cash | 8.48 | 2.71 | 2.95 | 2.66 |
| Total assets | 54.20 | 71.30 | 88.90 | 127 |
- Switch to
-
ConsolidatedStandalone
| Particulars ( Rupees In Crores.) | Sep-2019 | Jun-2019 | Sep-2018 | Jun-2018 | - |
|---|---|---|---|---|---|
| Gross Sales | 11.60 | 6.85 | 8.84 | 12 | -- |
| Excise Duty | -- | -- | -- | -- | -- |
| Net Sales | 11.60 | 6.85 | 8.84 | 12 | -- |
| Other Operating Income | -- | -- | -- | -- | -- |
| Other Income | 0.59 | 0.30 | -- | 0.09 | -- |
| Total Income | 12.20 | 7.15 | 8.80 | 12 | -- |
| Total Expenditure ** | 11.90 | 9.72 | 8.65 | 13.80 | -- |
| PBIDT | 0.22 | (2.60) | 0.15 | (1.70) | -- |
| Interest | 0.04 | 0.13 | 0.62 | 0.83 | -- |
| PBDT | 0.17 | (2.70) | (0.50) | (2.60) | -- |
| Depreciation | 0.72 | 1.02 | 0.75 | 1 | -- |
| Minority Interest Before NP | -- | -- | -- | -- | -- |
| Tax | -- | -- | -- | -- | -- |
| Deferred Tax | 0.04 | (1.60) | 0.05 | -- | -- |
| Reported Profit After Tax | (0.60) | (2.10) | (1.30) | (3.50) | -- |
| Minority Interest After NP | -- | -- | -- | -- | -- |
| Net Profit after Minority Interest | (0.60) | (2.10) | (1.30) | (3.50) | -- |
| Extra-ordinary Items | -- | -- | -- | -- | -- |
| Adjusted Profit After Extra-ordinary item | (0.60) | (2.10) | (1.30) | (3.50) | -- |
| EPS (Unit Curr.) | (0.30) | (0.90) | (0.80) | -- | -- |
| Book Value (Unit Curr.) | -- | -- | -- | -- | -- |
| Dividend (%) | -- | -- | -- | -- | -- |
| Equity | 23.70 | 23.70 | 23.70 | 23.70 | -- |
| Public Shareholding (Number) | -- | -- | -- | -- | -- |
| Public Shareholding (%) | -- | -- | -- | -- | -- |
| Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | -- |
| Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | -- |
| Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | -- |
| Non Encumbered - No. of Shares | -- | -- | -- | -- | -- |
| Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | -- |
| Non Encumbered - % in Total Equity | -- | -- | -- | -- | -- |
| PBIDTM(%) | 1.90 | (38) | 1.70 | (14) | -- |
| PBDTM(%) | 1.47 | (39) | (5.30) | (21) | -- |
| PATM(%) | (5.10) | (31) | (14) | (29) | -- |
QuickLinks for Bafna Pharmaceuticals Ltd.
